Adagrasib for Patients with KRAS G12C–Mutant NSCLC
Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.
EP: 1.Biomarker Testing in Non-Small Cell Lung Cancer
EP: 2.Liquid vs Tissue Biopsies in NSCLC
EP: 3.NSCLC: Biomarker Testing Strategies and Turnaround Time
EP: 4.Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC
EP: 5.Strategies to Improve Biomarker Testing in NSCLC
EP: 6.Treatment Options for Patients with NSCLC with EGFR Mutations
EP: 7.Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations
EP: 8.NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy
EP: 9.Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC
Now Viewing
EP: 10.Adagrasib for Patients with KRAS G12C–Mutant NSCLC
EP: 11.Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?
EP: 12.Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Related Videos
Related Content
